GlassScriptPhysician profile
Joseph B Clemente
NPI 1851462246
$1,749.57
in general payments reported to CMS, 2019-2025
25 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $217 · 2021: $211 · 2022: $330 · 2023: $416 · 2024: $164 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $878.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $444.68 | 2019-2025 | Lo Loestrin Fe, Orilissa |
| Exeltis, USA INC. | $146.46 | 2021-2025 | Slynd |
| Aspira Women'S Health INC | $139.01 | 2022-2023 | Ova1 |
| Coopersurgical, INC. | $123.04 | 2019-2025 | Paragard T 380a |
| Astellas Pharma US INC | $102.98 | 2023-2024 | Veozah |
| Biogen, INC. | $96.36 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $95.41 | 2021-2025 | |
| Hologic Sales and Service, LLC | $88.64 | 2020-2024 | Thinprep 2000 Processor, Aptima |
| Daiichi Sankyo INC. | $73.29 | 2024-2025 | Injectafer |
| Organon LLC | $68.84 | 2022-2025 | Nexplanon |
| Pfizer INC. | $50.13 | 2022 | |
| Exact Sciences Corporation | $40.82 | 2023-2025 | Cologuard Collection Kit |
| Mayne Pharma Commercial LLC | $37.58 | 2023-2025 | |
| Davol INC. | $36.61 | 2021-2023 | Arista Ah Flexitip |
| Meditrina | $34.03 | 2021-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $22.81 | 2023 | Accrufer |
| Ethicon US, LLC | $22.75 | 2019-2020 | |
| Si-Bone, INC. | $18.29 | 2019 | |
| Duchesnay USA Incorporated | $17.86 | 2019 | |
| Sumitomo Pharma America, INC. | $17.35 | 2023 | Myfembree |
| Vertex Pharmaceuticals Incorporated | $16.37 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $15.92 | 2021 | |
| Smith+Nephew, INC. | $14.56 | 2020 | |
| Glaxosmithkline, LLC. | $14.54 | 2022 | |
| Vertical Pharmaceuticals, LLC | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Clemente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.